DexCom, Inc. is contending with a 20.74% decline in stock price as it approaches its first-quarter 2026 earnings report on April 30, with shares currently priced at $64.62. Despite these challenges, the company has maintained strong revenue growth at 17.4% annually over the last three years and is projected to grow at 15.2% going forward. Recent FDA approval for Stelo, an over-the-counter continuous glucose monitoring device, positions DexCom to expand its market share amid significant competition from Abbott Laboratories. DexCom's strategy to capitalize on the growing CGM market, particularly through the prescription of weight loss drugs alongside its devices, further underscores its potential for recovery.
“DexCom, Inc. · share price · $64.62 · as of April 20th”
“DexCom, Inc. · P/E ratio · trailing · 30.92”
“DexCom, Inc. · P/E ratio · forward · 25.91”
“DexCom, Inc. · revenue growth · past three years · 17.4% annually”
“DexCom, Inc. · projected growth · going forward · 15.2%”
“DXCM · hedge fund portfolios · held at end of fourth quarter · 71”
“DXCM · stock price depreciation · since previous coverage · 20.74%”
“Dexcom · develops and sells · continuous glucose monitoring (CGM) devices”
“Dexcom · can expand · its addressable market”
“Dexcom · earned clearance for · Stelo, an over-the-counter CGM option”
“Dexcom · is well-positioned to capitalize on · the growth of the CGM market”
“DexCom, Inc. · is scheduled to report · first-quarter 2026 results · April 30”